Cardiometabolic diseases

Type 2 diabetes progresses very differently from patient to patient, and so does the response to therapy. We use models to describe how blood glucose, HbA1c and organ function develop over time and how antidiabetic and cardiovascular drugs affect them. The aim is to identify the right therapy for individual patients earlier.

How we work

We combine disease progression models with quantitative systems pharmacology and PBPK models, for example for metformin, incretins and SGLT inhibitors. Among other sources, we use data from large European cohorts.

Network

We were a partner in the European IMI project DIRECT (Diabetes Research on Patient Stratification).

Selected publications

• Balazki P, Schaller S, Eissing T, Lehr T. A physiologically-based quantitative systems pharmacology model of the incretin hormones GLP-1 and GIP and the DPP4 inhibitor sitagliptin. CPT Pharmacometrics Syst Pharmacol. 2020;9(6):353-362.
• Hanke N, Türk D, Selzer D, … Lehr T. A comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet. 2020;59:1419-1431.
• Balazki P, Schaller S, Eissing T, Lehr T. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):788-797.